Table 10.

Key clinical and cost-effectiveness results for Originator versus pooled biosimilars

	Originator	Pooled biosimilars	Difference
Live birth rate	36.0%	30.1%	5.9%
Total costs (€)a	4,207	3,777	430
Gonadotropin costs (€)	1,114	892	222
Adverse event costs (€)	15	17	−2
Assisted reproduction costs (€)	1,746	1,754	−8
Birth costs (€)	1,332	1,113	218
Cost per live birth (€)	11,676	12,547
ICER (€)	7,256

Note: ^aCost breakdowns were estimated as the average cost for women within each treatment arm.

Abbreviation: ICER, incremental cost-effectiveness ratio.